AXIM - Medical Marijuana Is Undervalued At 3.2x Forward Sales
With Q1 revenue growing at 92% y/y and a gross profit of 78%, Medical Marijuana (MJNA) recently surprised the market. The quarterly results were beneficial, and the company is undervalued at 3.2x forward sales. Other competitors are trading at much higher valuations. If MJNA continues delivering favorable revenue growth, the share price should increase. Market participants will most likely accept paying $0.21 per share.
Business Model
Medical Marijuana Inc. is focused on the development, sale, and distribution of hemp oil containing cannabinoids.Source: Company’s Website
It is impossible to review all the hemp